Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3935135
Max Phase: Preclinical
Molecular Formula: C21H26N4O4
Molecular Weight: 398.46
Molecule Type: Small molecule
Associated Items:
ID: ALA3935135
Max Phase: Preclinical
Molecular Formula: C21H26N4O4
Molecular Weight: 398.46
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(NC[C@@H](C(=O)NO)N1CCCCC1)c1ccc(OCc2ccncc2)cc1
Standard InChI: InChI=1S/C21H26N4O4/c26-20(23-14-19(21(27)24-28)25-12-2-1-3-13-25)17-4-6-18(7-5-17)29-15-16-8-10-22-11-9-16/h4-11,19,28H,1-3,12-15H2,(H,23,26)(H,24,27)/t19-/m0/s1
Standard InChI Key: ZTDRQXAWZXLROA-IBGZPJMESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 398.46 | Molecular Weight (Monoisotopic): 398.1954 | AlogP: 1.75 | #Rotatable Bonds: 8 |
Polar Surface Area: 103.79 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 8.72 | CX Basic pKa: 6.31 | CX LogP: 1.15 | CX LogD: 1.09 |
Aromatic Rings: 2 | Heavy Atoms: 29 | QED Weighted: 0.46 | Np Likeness Score: -0.98 |
1. (2016) 4-alkoxy-N-(2-hydroxycarbamoyl-2-piperidinyl-ethyl)-benzamide compounds as selective TACE-inhibitors for the treatment of inflammatory diseases, |
Source(1):